RT Journal Article SR Electronic T1 Risk Factors for Totally Implantable Central Venous Access Port-related Infection in Patients With Malignancy JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 1547 OP 1553 DO 10.21873/anticanres.14914 VO 41 IS 3 A1 SATORU FURUHASHI A1 YOSHIFUMI MORITA A1 SHINYA IDA A1 RYUTA MURAKI A1 RYO KITAJIMA A1 KATSUNORI SUZUKI A1 MAKOTO TAKEDA A1 HIROTOSHI KIKUCHI A1 YOSHIHIRO HIRAMATSU A1 KIYOTAKA KURACHI A1 YOJI SHIDO A1 KEN SUGIMOTO A1 HIROAKI ITO A1 YUICHIRO MAEKAWA A1 HIROYUKI MINETA A1 HIDEAKI MIYAKE A1 HIROYA TAKEUCHI YR 2021 UL http://ar.iiarjournals.org/content/41/3/1547.abstract AB Background: We sought to identify the risk factors of totally implantable central venous access port (TICVAP)-related infections in patients with malignant disease. Patients and Methods: Overall, 324 consecutive patients who received a TICVAP at our institution were retrospectively analysed. We further analysed cases of TICVAP-related complications. The risk factors for TICVAP-related infection were investigated using Cox regression hazard models. Results: With a median TICVAP duration of 268 days (range=1-1,859 days), TICVAP-related complications were observed in 36 cases and infectious complications in late phase were the most common, seen in 19 cases (9.26%). A multivariate analysis showed that patients with head and neck malignancy (p<0.001) and patients who received TICVAP insertion in the upper arm (p<0.001) were independently at a higher risk for TICVAP-related infections. Conclusion: Patients with head and neck malignancy or TICVAP insertion in the upper arm have potentially increased risk for late-phase TICVAP-related infections.